BioNTech says has vaccine pricing benchmark for rich countries for similar volumes

Syringes are seen in front of a displayed Biontech logo in this illustration taken November 10, 2020. REUTERS/Dado Ruvic/Illustration

FRANKFURT (Reuters) - BioNTech BNTX.O on Tuesday signalled that order size would impact the per-dose price for its potential COVID-19 vaccine in the developed world.

“The price for the U.S. for the first 100 million doses was $19.50 per dose,” said BioNTech’s Chief Strategy Officer Ryan Richardson in an analyst call after the release of third quarter results on Tuesday.

He was referring to a July deal struck by partner Pfizer PFE.N with the U.S. government for the supply of the vaccine.

“You can think about that as a benchmark for how we would price the vaccine to the developed world for similar volumes,” he added.

Reporting by Ludwig Burger; Editing by Edward Taylor